[go: up one dir, main page]

WO2000046193A3 - Ether derivatives having neuronal activity - Google Patents

Ether derivatives having neuronal activity Download PDF

Info

Publication number
WO2000046193A3
WO2000046193A3 PCT/US2000/002773 US0002773W WO0046193A3 WO 2000046193 A3 WO2000046193 A3 WO 2000046193A3 US 0002773 W US0002773 W US 0002773W WO 0046193 A3 WO0046193 A3 WO 0046193A3
Authority
WO
WIPO (PCT)
Prior art keywords
ether derivatives
neuronal activity
compounds
formula
relates
Prior art date
Application number
PCT/US2000/002773
Other languages
French (fr)
Other versions
WO2000046193A2 (en
Inventor
Thomas Brumby
Fiona Mcdonald
Eckhard Ottow
Herbert Schneider
Original Assignee
Schering Ag
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999105254 external-priority patent/DE19905254A1/en
Application filed by Schering Ag, Vertex Pharma filed Critical Schering Ag
Priority to AU35873/00A priority Critical patent/AU3587300A/en
Publication of WO2000046193A2 publication Critical patent/WO2000046193A2/en
Publication of WO2000046193A3 publication Critical patent/WO2000046193A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the compounds of Formula (I), as well as the process for their production and their use as pharmaceutical agents. The invention also relates to the compounds of Formula (IA), their isomers and physiologically compatible salts.
PCT/US2000/002773 1999-02-03 2000-02-03 Ether derivatives having neuronal activity WO2000046193A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35873/00A AU3587300A (en) 1999-02-03 2000-02-03 Ether derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE1999105254 DE19905254A1 (en) 1999-02-03 1999-02-03 New ether compounds, useful for treating neurological diseases e.g. Parkinson's disease, amyotrophic lateral sclerosis and Alzheimer's disease
DE19905254.9 1999-02-03
US12600899P 1999-03-24 1999-03-24
US60/126,008 1999-03-24
US49627900A 2000-02-01 2000-02-01
US09/496,279 2000-02-01

Publications (2)

Publication Number Publication Date
WO2000046193A2 WO2000046193A2 (en) 2000-08-10
WO2000046193A3 true WO2000046193A3 (en) 2000-12-21

Family

ID=27218962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002773 WO2000046193A2 (en) 1999-02-03 2000-02-03 Ether derivatives having neuronal activity

Country Status (2)

Country Link
AU (1) AU3587300A (en)
WO (1) WO2000046193A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229630A2 (en) * 1986-01-16 1987-07-22 Hoechst Aktiengesellschaft 1,2-Disubstituted piperidines, process for their preparation and their use as herbicides
WO1996040682A1 (en) * 1995-06-07 1996-12-19 Abbott Laboratories 3-pyridyloxyalkyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
WO1996041609A2 (en) * 1995-06-08 1996-12-27 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
WO1997046554A1 (en) * 1996-06-06 1997-12-11 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
WO1999032480A1 (en) * 1997-12-19 1999-07-01 Abbott Laboratories Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission
WO1999062881A1 (en) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Aza-heterocyclic compounds used to treat neurological disorders and hair loss
WO1999065451A2 (en) * 1998-06-18 1999-12-23 Smithkline Beecham Corporation Caspases and apoptosis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229630A2 (en) * 1986-01-16 1987-07-22 Hoechst Aktiengesellschaft 1,2-Disubstituted piperidines, process for their preparation and their use as herbicides
WO1996040682A1 (en) * 1995-06-07 1996-12-19 Abbott Laboratories 3-pyridyloxyalkyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
WO1996041609A2 (en) * 1995-06-08 1996-12-27 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
WO1997046554A1 (en) * 1996-06-06 1997-12-11 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
WO1999032480A1 (en) * 1997-12-19 1999-07-01 Abbott Laboratories Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission
WO1999062881A1 (en) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Aza-heterocyclic compounds used to treat neurological disorders and hair loss
WO1999065451A2 (en) * 1998-06-18 1999-12-23 Smithkline Beecham Corporation Caspases and apoptosis

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BYUN, IL SUK ET AL: "Highly diastereoselective reduction of new chiral.alpha.-keto amides", SYNTH. COMMUN. (1995), 25(13), 1963-9, XP000916268 *
CHOJI KASHIMA ET AL.: "Lithium Aluminium Hydride Reduction of Chiral Benzoylformamides Derivwd from Chiral Amino Alcohols", J. CHEM. PERKINS TRANS I, 1987, pages 1495 - 15000, XP000916103 *
FUJISAWA, TAMOTSU ET AL: "Stereocontrolled addition reaction of organometallics to chiral.alpha.-keto amides", BULL. CHEM. SOC. JPN. (1990), 63(7), 1894-7, XP000916071 *
HAMILTON G S: "IMMUNOPHILIN LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS", EXPERT OPINION ON THERAPEUTIC PATENTS,GB,ASHLEY PUBLICATIONS, vol. 8, no. 9, 1998, pages 1109 - 1124, XP000852684, ISSN: 1354-3776 *
IBUKA, TOSHIRO ET AL: "Aza-Payne Rearrangement of Activated 2-Aziridinemethanols and 2,3-Epoxy Amines under Basic Conditions", J. ORG. CHEM. (1995), 60(7), 2044-58, 1995, XP000916214 *
KOFT, EMIL R. ET AL: "The formation and alkylation of.alpha.-keto amide dianions", TETRAHEDRON LETT. (1986), 27(20), 2227-30, XP000916202 *
NKUNYA, M. H. H. ET AL: "Asymmetric synthesis of.alpha.,.beta.-epoxy sulfonamides (oxiranesulfonamides)", RECL. TRAV. CHIM. PAYS-BAS (1985), 104(10), 253-9, 1985, XP000916218 *
OKAMOTO, YOSHIO ET AL: "Asymmetric polymerization of aromatic isocyanates with optically active anionic initiators", J. POLYM. SCI., PART A: POLYM. CHEM. (1994), 32(2), 309-15, XP000424261 *
THOMAS R M ET AL: "An efficient and selective deprotection of allyl ethers by a CeCl3.7H2O- NaI system", TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 40, no. 40, 1 October 1999 (1999-10-01), pages 7293 - 7294, XP004179039, ISSN: 0040-4039 *
TSUGE H ET AL: "Highly Diastereoselective Michael Addition to Optically Active Trifluoromethylated alpha,beta-Unsaturated Sulfonamides Based on Their Hinge-Like Conformation", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 53, no. 3, 20 January 1997 (1997-01-20), pages 823 - 838, XP004105184, ISSN: 0040-4020 *
VAN DEN BROEK, LEON A. G. M. ET AL: "Asymmetric Diels-Alder reactions with sulfines derived from proline", J. ORG. CHEM. (1984), 49(10), 1691-5, 1984, XP000916217 *

Also Published As

Publication number Publication date
AU3587300A (en) 2000-08-25
WO2000046193A2 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
WO2000061568A3 (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
RS50140B (en) Percyquinnin, a process for its production, and its use as a pharmaceutical
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
WO2001032646A3 (en) Sulfonamide derivatives
UA74346C2 (en) Aminodicarboxylic acids derivatives, use thereof and a medicament
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
WO2001019776A3 (en) Novel derivatives of dicarboxylic acid having pharmaceutical properties
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
YU7804A (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
WO2003006443A3 (en) 2- 4-(naphtalin-2-yl)-thiazol-2-ylaminocarbonyl benzoic acid and 2- 4-(naphtalin-2-yl)-pyrimidin-2-ylaminocarbonyl benzoic acid and additional compounds serving as telomerase inhibitors for use in tumor therapy
WO2002010152A3 (en) Novel indole derivatives and their use as medicaments
CA2429133A1 (en) Novel imidazole derivatives, production method thereof and use thereof
HUP0002963A3 (en) Use of pyrazolo-[4,3-d] pyrimidinon derivatives for the production of pharmaceutical compositions for treating diseases of the eye field
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
WO2004106307A3 (en) Novel imidazole derivatives, the production thereof, and the use of the same as a medicament
EP1019047A4 (en) Antithrombotic agents
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
HK1041000B (en) Novel pyrimidine derivatives and processes for the preparation thereof
HUP0103912A3 (en) Substituted alkylpyridazinone derivatives, process for their preparation, their use for the preparation of pharmaceutical compositions with anxiolytic activity
WO2000046193A3 (en) Ether derivatives having neuronal activity
WO2000076966A3 (en) Indolinylamide derivatives and the use thereof as antiviral drugs
WO1998056759A3 (en) Novel pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same
HUP0000982A2 (en) Process for the preparation of 1,1-dioxo-penicillanic acid derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase